Trials / Completed
CompletedNCT00051129
Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 291 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate anecortave acetate compared to placebo for maintenance of visual acuity after 24 months of treatment in patients with subfovial choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD).
Conditions
- Macular Degeneration
- Maculopathy, Age-Related
- Age-Related Maculopathies
- Age-Related Maculopathy
- Maculopathies, Age-Related
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anecortave Acetate 15 mg sterile suspension | 0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection |
| OTHER | Anecortave Acetate Vehicle | Administered as a posterior juxtascleral injection |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2003-01-07
- Last updated
- 2012-11-28
Source: ClinicalTrials.gov record NCT00051129. Inclusion in this directory is not an endorsement.